The Efficacy and Safety of Switching to Flumatinib Versus Dasatinib After Imatinib-related Low-grade Adverse Events in CML-CP Patients

Name: The Efficacy and Safety of Switching to Flumatinib Versus Dasatinib After Imatinib-related Low-grade Adverse Events in CML-CP Patients
Published: 2021
License: Public Domain

Shenzhen Second People's Hospital · 2021

ClinicalTrials.gov · Datasets · License: Public Domain · 2021

Open Source ↗

chronic myeloid leukemia in chronic phase, imatinib, flumatinib, dasatinib, interventional, phase4

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

The Efficacy and Safety of Switching to Flumatinib Versus Dasatinib After Imatinib-related Low-grade Adverse Events in CML-CP Patients

Related documents